Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Australia.
Rheumatology Group, School of Medicine, University of Western Australia, 35 Stirling Highway (M503), Perth, WA, Australia.
Rheumatol Int. 2024 Feb;44(2):329-337. doi: 10.1007/s00296-023-05475-3. Epub 2023 Oct 11.
To determine long term overall and subgroup specific incidence rates and associated mortality for idiopathic inflammatory myopathies (IIM) in a population wide study. We included patients hospitalised between 1980 and 2015 with incident IIM as defined by relevant diagnostic codes for dermatomyositis (DM) polymyositis (PM), inclusion body myositis (IBM), other IIM and overlap myositis (OM) in the Western Australia Health Hospital Morbidity Data Collection (n = 846). Trends over time for annual incidence rate per million population (AIR) were analysed by least square regression and Kaplan-Meier survival and mortality rates (MR)/100 person years compared with a matched control group (n = 3681). The averaged AIR for all IIM was 19 (CI 10.4-27.5) and stable over time with point prevalence reaching 205.3 (CI 185.6-226.6) per million in 2015. Over time, the AIR for DM 5.0 (CI 0.6-9.4) and IBM 3.3 (CI 0.7-9.6) was stable, while AIR decreased for PM (p < 0.01) and increased for other IIM (p < 0.01) and OM (p < 0.01). IBM patients were eldest at diagnosis (68 years, CI 59-77) with male preponderance in IBM (53.4%) and other IIM (55.8%) groups. Crude mortality (54.5 vs 41.3%), MR ratio (6.65 vs 5.91) and 5 (65.8% vs 71.6%) and 10-year (52.5% vs 58.7%) survival were all worse for IIM patients (all p < 0.05). IBM patients had highest MR (10.1; CI 8.38-12.14) and lowest 10-year survival (39.2%). While cardiovascular disease and cancer were predominant causes of death, they were proportionally lower in IIM patients, where respiratory and rheumatic disease were more frequent causes of death. While the overall incidence of IIM in WA was stable over 35 years, the spectrum of IIM has changed significantly with increases especially in other IIM and OM. The overall prognosis with IIM remains guarded with 10-year survival just over 50%.
为了在一项全人群研究中确定特发性炎症性肌病(IIM)的长期总体和亚组特定发病率以及相关死亡率。我们纳入了 1980 年至 2015 年期间因相关诊断代码而住院的特发性炎症性肌病患者,这些代码用于诊断皮肌炎(DM)、多发性肌炎(PM)、包涵体肌炎(IBM)、其他 IIM 和重叠肌炎(OM)(n=846)。通过最小二乘回归和 Kaplan-Meier 生存分析,分析了每年每百万人发病率(AIR)的趋势,并与匹配的对照组(n=3681)进行了比较。所有 IIM 的平均 AIR 为 19(CI 10.4-27.5),且随时间稳定,2015 年时点患病率达到 205.3(CI 185.6-226.6)/百万。随着时间的推移,DM 的 AIR 为 5.0(CI 0.6-9.4)和 IBM 的 AIR 为 3.3(CI 0.7-9.6)保持稳定,而 PM 的 AIR 下降(p<0.01),其他 IIM(p<0.01)和 OM(p<0.01)的 AIR 增加。IBM 患者的诊断年龄最大(68 岁,CI 59-77),IBM(53.4%)和其他 IIM(55.8%)组男性居多。未校正死亡率(54.5%比 41.3%)、死亡率比(6.65 比 5.91)和 5 年(65.8%比 71.6%)和 10 年(52.5%比 58.7%)生存率均较差(均 p<0.05)。IBM 患者的死亡率最高(10.1;CI 8.38-12.14),10 年生存率最低(39.2%)。心血管疾病和癌症虽然是主要死亡原因,但在 IIM 患者中比例较低,呼吸系统和风湿性疾病是更常见的死亡原因。尽管 WA 35 年来 IIM 的总体发病率保持稳定,但 IIM 的谱已发生显著变化,尤其是其他 IIM 和 OM 的发病率增加。IIM 的总体预后仍不容乐观,10 年生存率仅略高于 50%。